These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Effect of angiotensin on the central action of dopamine. Braszko J; Wiśniewski K Pol J Pharmacol Pharm; 1976; 28(6):667-72. PubMed ID: 1034924 [TBL] [Abstract][Full Text] [Related]
3. Catalepsy, sedation and hypothermia induced by alpha-methyl-p-tyrosine in the rat. An ideal tool for screening of drugs active on central catecholaminergic receptors. Papeschi R; Randrup A Pharmakopsychiatr Neuropsychopharmakol; 1973 May; 6(3):137-57. PubMed ID: 4800160 [No Abstract] [Full Text] [Related]
4. Stimulation of postsynaptic alpha1b- and alpha2-adrenergic receptors amplifies dopamine-mediated locomotor activity in both rats and mice. Villégier AS; Drouin C; Bizot JC; Marien M; Glowinski J; Colpaërt F; Tassin JP Synapse; 2003 Dec; 50(4):277-84. PubMed ID: 14556232 [TBL] [Abstract][Full Text] [Related]
5. Antagonism by neuroleptics of abnormal behavior induced by activation of brain dopamine receptors. Van Rossum JM Mod Probl Pharmacopsychiatry; 1970; 5():65-7. PubMed ID: 5527171 [No Abstract] [Full Text] [Related]
6. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. Perrault G; Depoortere R; Morel E; Sanger DJ; Scatton B J Pharmacol Exp Ther; 1997 Jan; 280(1):73-82. PubMed ID: 8996184 [TBL] [Abstract][Full Text] [Related]
8. Neurochemical and behavioral evidence that Ro 41-9067 is a selective presynaptic dopamine receptor agonist. Nisoli E; Tonello C; Imhof R; Scherschlicht R; da Prada M; Carruba MO J Pharmacol Exp Ther; 1993 Jul; 266(1):97-105. PubMed ID: 8101225 [TBL] [Abstract][Full Text] [Related]
9. Effects of buspirone on dopamine dependent behaviours in rats. Dhavalshankh AG; Jadhav SA; Gaikwad RV; Gaonkar RK; Thorat VM; Balsara JJ Indian J Physiol Pharmacol; 2007; 51(4):375-86. PubMed ID: 18476392 [TBL] [Abstract][Full Text] [Related]
10. Comparative effects of dl-p-methoxyamphetamine and d-amphetamine on catecholamine release and reuptake in vitro. Tseng LF; Hitzemann RJ; Loh HH J Pharmacol Exp Ther; 1974 Jun; 189(3):708-16. PubMed ID: 4843169 [No Abstract] [Full Text] [Related]
11. [Effect of repeated haloperidol and apomorphine administration on the development of tolerance for catalepsy and dopamine receptor hypersensitivity in mice]. Zharkovskiĭ AM; Matvienko OA; Nurk AM Biull Eksp Biol Med; 1984 Oct; 98(10):444-6. PubMed ID: 6541951 [TBL] [Abstract][Full Text] [Related]
12. A comparison of the effects of d-amphetamine and morphine upon the locomotor activity of mice treated with drugs which alter brain catecholamine content. Villarreal JE; Guzman M; Smith CB J Pharmacol Exp Ther; 1973 Oct; 187(1):1-7. PubMed ID: 4746328 [No Abstract] [Full Text] [Related]
13. Effects of d-amphetamine and apomorphine upon operant behavior and schedule-induced licking in rats with 6-hydroxydopamine-induced lesions of the nucleus accumbens. Robbins TW; Roberts DC; Koob GF J Pharmacol Exp Ther; 1983 Mar; 224(3):662-73. PubMed ID: 6402587 [TBL] [Abstract][Full Text] [Related]
14. Sensorimotor gating effects produced by repeated dopamine agonists in a paradigm favoring environmental conditioning. Feifel D; Priebe K; Johnstone-Miller E; Morgan CJ Psychopharmacology (Berl); 2002 Jul; 162(2):138-46. PubMed ID: 12110991 [TBL] [Abstract][Full Text] [Related]
15. Prefrontal cortical and hippocampal modulation of haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors in the rat. Lipska BK; Jaskiw GE; Braun AR; Weinberger DR Biol Psychiatry; 1995 Aug; 38(4):255-62. PubMed ID: 8547448 [TBL] [Abstract][Full Text] [Related]
16. The influence of antineoplaston A5 on the central dopaminergic structures. Juszkiewicz M; Chodkowska A; Burzynski SR; Feldo M; Majewska B; Kleinrok Z Drugs Exp Clin Res; 1994; 20(4):161-7. PubMed ID: 7813388 [TBL] [Abstract][Full Text] [Related]
17. Potentiation of haloperidol-induced catalepsy by dopamine agonists: possible involvement of central 5-hydroxytryptamine. Carter CJ; Pycock CJ Pharmacol Biochem Behav; 1979 Apr; 10(4):475-80. PubMed ID: 572550 [TBL] [Abstract][Full Text] [Related]
18. Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice. Moreira FA; Guimarães FS Eur J Pharmacol; 2005 Apr; 512(2-3):199-205. PubMed ID: 15840405 [TBL] [Abstract][Full Text] [Related]
19. Modification of striatal acetylcholine concentration by dopamine receptor agonists and antagonists. Sethy VH; VAN Woert MH Res Commun Chem Pathol Pharmacol; 1974 May; 8(1):13-28. PubMed ID: 4847901 [No Abstract] [Full Text] [Related]
20. Pharmacological studies on tetrabenazine-induced excited behaviour of rats pretreated with amphetamine or nialamide. Scheel-Krüger J; Jonas W Arch Int Pharmacodyn Ther; 1973 Nov; 206(1):47-65. PubMed ID: 4798103 [No Abstract] [Full Text] [Related] [Next] [New Search]